Beta cell

Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes

Retrieved on: 
Tuesday, December 8, 2020
Branches of biology, Clinical medicine, Medicine, Diabetes, Novo Nordisk, Peptide hormones, Recombinant proteins, Insulin, Cell encapsulation, Beta cell, Type 1 diabetes

The collaboration brings together Procyon Technologies' expertise with development of oxygen enabled implantable cell encapsulation devices and Novo Nordisk's expertise in stem cell-derived insulin-secreting cells.

Key Points: 
  • The collaboration brings together Procyon Technologies' expertise with development of oxygen enabled implantable cell encapsulation devices and Novo Nordisk's expertise in stem cell-derived insulin-secreting cells.
  • In addition, Procyon Technologies will receive tiered sales milestones and royalties on the annual net sales of the products resulting from the collaboration.
  • Novo Nordisk will be responsible for the development, manufacturing and commercialization of the products resulting from the collaboration for Type 1 diabetes.
  • "The partnership between Procyon Technologies and Novo Nordisk represents the culmination of years of hard work and will revolutionize the care of people with Type 1 diabetes."

New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes

Retrieved on: 
Tuesday, September 22, 2020
Clinical medicine, Branches of biology, Medicine, RTT, Biomarkers, Medical signs, Diabetes, 1,5-Anhydroglucitol, Type 1 diabetes, Beta cell

The authors conclude, "our results suggest that circulating levels of 1,5-anhydroglucitol (GlycoMark) reflect beta-cell functional mass in humans.

Key Points: 
  • The authors conclude, "our results suggest that circulating levels of 1,5-anhydroglucitol (GlycoMark) reflect beta-cell functional mass in humans.
  • GlycoMark is available at major reference laboratories in the United States and throughout the world.
  • Precision Diabetes, Inc. (Raleigh, North Carolina) is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region, the Middle East, and Mexico.
  • Precision Diabetes is an emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms.

New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes

Retrieved on: 
Tuesday, September 22, 2020
Clinical medicine, Branches of biology, Medicine, RTT, Biomarkers, Medical signs, Diabetes, 1,5-Anhydroglucitol, Type 1 diabetes, Beta cell

The authors conclude, "our results suggest that circulating levels of 1,5-anhydroglucitol (GlycoMark) reflect beta-cell functional mass in humans.

Key Points: 
  • The authors conclude, "our results suggest that circulating levels of 1,5-anhydroglucitol (GlycoMark) reflect beta-cell functional mass in humans.
  • GlycoMark is available at major reference laboratories in the United States and throughout the world.
  • Precision Diabetes, Inc. (Raleigh, North Carolina) is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region, the Middle East, and Mexico.
  • Precision Diabetes is an emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms.

DGAP-News: EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY

Retrieved on: 
Wednesday, April 22, 2020
Branches of biology, Life sciences, Stem cells, Biology, Evotec, Stem-cell therapy, Induced pluripotent stem cell, Cell therapy, Therapy, Beta cell

Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering the generation of iPS cell lines, up to cell manufacturing of various cell types for drug screening as well as GMP production of clinical material for cell therapies.

Key Points: 
  • Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering the generation of iPS cell lines, up to cell manufacturing of various cell types for drug screening as well as GMP production of clinical material for cell therapies.
  • Evotec will continue the development of the beta cell programme on its own within its EVT Innovate initiative "QRbeta Therapeutics".
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Evotec and Sanofi have developed the beta cell replacement therapy programme since 2015 in a highly productive partnership.
  • Furthermore, beta cell replacement therapy also has the potential to prevent or reverse the decline in beta cell function in type 2 diabetes.

JDRF Reaches New Milestones in Work to Drive Cures for Type 1 Diabetes and Improve Lives

Retrieved on: 
Friday, February 14, 2020
Organ systems, RTT, Endocrine system, Medicine, JDRF, Beta cell, Type 1 diabetes, Diabetes, The Environmental Determinants of Diabetes in the Young, Juvenile Diabetes Cure Alliance

The organization also supported new investment through the JDRF T1D Fund in 15 T1D companies, including 11 focused on cures.

Key Points: 
  • The organization also supported new investment through the JDRF T1D Fund in 15 T1D companies, including 11 focused on cures.
  • "We are focused on beta cell therapies and immune therapies to deliver cures for T1D," Kowalski said.
  • "At the same time, we continue accelerating work in glucose control and complication therapies to improve the lives of those living with type 1 diabetes today."
  • "JDRF works to build partnerships that advance research and build and sustain critical support for type 1 diabetes (T1D) research funded by the Federal Government."

Mount Sinai Discovers New Drug Combo to Induce High Rates of Human Beta Cell Regeneration

Retrieved on: 
Wednesday, February 12, 2020
Branches of biology, Organ systems, Medicine, Diabetes, RTT, Beta cell, Type 2 diabetes, Pancreatic islets, Type 1 diabetes

A deficiency of functioning beta cells is also an important contributor to type 2 diabetes, the most common type of diabetes.

Key Points: 
  • A deficiency of functioning beta cells is also an important contributor to type 2 diabetes, the most common type of diabetes.
  • Thus, developing drugs that can increase the number of healthy beta cells is a major priority in diabetes research.
  • According to Dr. Stewart, none of the diabetes drugs currently on the market can induce beta cell regeneration in people with diabetes.
  • In parallel with the Mount Sinai work, other researchers are studying pancreatic transplantation, beta cell transplantation, and stem cell replacement of beta cells for people with diabetes, but none of these approaches is in widespread use.

Islet Amyloid Polypeptide, Pipeline Review, H1 2020 - Areas such as Metabolic Disorders, Central Nervous System, Gastrointestinal & Musculoskeletal Disorders - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 29, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, Proteins, Peptide hormones, Organ systems, Amylin, Amyloid, IAPP, Peptide, Insulin, Amylin family, Beta cell

The "Islet Amyloid Polypeptide - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Islet Amyloid Polypeptide - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 12 molecules.
  • The latest report Islet Amyloid Polypeptide - Pipeline Review, H1 2020, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone.

MSC-donated mitochondria increase functional viability of islet beta cell transplantation for treating diabetes

Retrieved on: 
Wednesday, January 8, 2020
Branches of biology, Biology, Mitochondria, Cellular respiration, Mitochondrion, Stem cells, Beta cell, Diabetes, Horizontal transfer of mitochondria, Induced stem cells

But the STEM CELLSSC study is the first to show that mitochondria the organelles that power a cell are what is behind the improvement.

Key Points: 
  • But the STEM CELLSSC study is the first to show that mitochondria the organelles that power a cell are what is behind the improvement.
  • "When mitochondria are impaired, islet -cells can't produce insulin effectively, and they also tend to die off.
  • Full caption for figure: Human Mesenchymal Stromal Cells transfer mitochondria to neighboring human islet beta cells in direct contact co-culture.
  • Ensuring optimal beta cell mitochondrial mass and bioenergetics through MSC-mediated mitochondria transfer offers a novel strategy for improving the outcomes of clinical islet transplantation as a therapy for Type 1 Diabetes.

ViaCyte to Present at Biotech Showcase 2020 in San Francisco

Retrieved on: 
Wednesday, January 8, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell culture, Stem-cell line, Beta cell, Type 1 diabetes, Induced stem cells

SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. will present at Biotech Showcase 2020, to be held January 13 to 15 at the Hilton San Francisco Union Square.

Key Points: 
  • SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. will present at Biotech Showcase 2020, to be held January 13 to 15 at the Hilton San Francisco Union Square.
  • With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.
  • More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells mature into glucose-responsive insulin producing cells in patients with type 1 diabetes.
  • For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter , Facebook , and LinkedIn.

Global Type 1 Diabetes Market Report 2019: T1D Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 3, 2019
Health, Pharmaceutical, Organ systems, Endocrine system, Medicine, Eli Lilly and Company, RTT, Peptide hormones, Recombinant proteins, Insulin, Beta cell, Diabetes

The "Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration" report has been added to ResearchAndMarkets.com's offering.
  • Insulin is currently the mainstay treatment for T1D patients, and insulin therapy has significantly evolved over the last 90 years.
  • Still, there is a pressing unmet need within T1D treatment landscape for more diverse, non-insulin disease-modifying pharmacotherapies (immunomodulatory or -cell preservation).
  • Which molecular target classes are prominently represented in the overall and first-in-class T1D pipeline?